title: Keratoacanthomas associated with sorafenib therapy.
authors.forename: Heidi H
authors.initials: HH
authors.lastname: Kong
authors.forename: Edward W
authors.initials: EW
authors.lastname: Cowen
authors.forename: Nilofer S
authors.initials: NS
authors.lastname: Azad
authors.forename: William
authors.initials: W
authors.lastname: Dahut
authors.forename: Martin
authors.initials: M
authors.lastname: Gutierrez
authors.forename: Maria L
authors.initials: ML
authors.lastname: Turner
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001132:Arm; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D005148:Facial Dermatoses / Q000139:chemically induced; D005260:Female; D006801:Humans; D007636:Keratoacanthoma / Q000139:chemically induced* / Q000601:surgery; D007890:Leiomyosarcoma / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009333:Neck; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011471:Prostatic Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced* / Q000601:surgery; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib